RealVision

RealVision is an early-stage digital health venture developing an AI-enabled smartphone application for early identification of neuropsychiatric and neurodegenerative disorders. The product uses digital phenotyping, including analysis of speech, facial cues, eye movement, typing behavior, and other smartphone-derived behavioral markers, to flag subtle changes associated with conditions such as Alzheimer's disease and related dementias. Publicly available information indicates the technology is being advanced through Dartmouth-affiliated research and innovation programs rather than as a mature commercial biopharma company. RealVision appears focused on screening and risk detection rather than therapeutics, with potential use in clinics and caregiver-supported monitoring workflows. The available evidence suggests it is a healthcare technology startup or venture concept in active development.